Injections in the osteoarthritic knee: a review of current treatment options

Abstract

Knee osteoarthritis is a degenerative condition characterized by progressive cartilage degradation, subchondral damage, and bone remodelling. Among the approaches implemented to achieve symptomatic and functional improvements, injection treatments have gained increasing attention due to the possibility of intra-articular delivery with reduced side effects compared to systemic therapies. In addition to well-established treatment options such as hyaluronic acid (HA), cortico-steroids (CS) and oxygen-ozone therapy, many other promising products have been employed in the last decades such as polydeoxyribonucleotide (PDRN) and biologic agents such as platelet-rich plasma (PRP) and mesenchymal stem cells (MSCs). Moreover, ultrasound-guided intra-meniscal injection and X-ray-guided subchondral injection techniques have been introduced into clinical practice. Even when not supported by high evidence consensus, intra-articular CS and HA injections have gained precise indications for symptomatic relief and clinical improvement in OA. Biological products are strongly supported by in vitro evidence but there is still a lack of robust clinical evidence. PRP and MSCs seem to relieve OA symptoms through a regulation of the joint homeostasis, even if their capability to restore articular cartilage is still to be proved in vivo. Due to increasing interest in the subchondral bone pathology, subchondral injections have been developed with promising results in delaying joint replacement. Nevertheless, due to their recent development and the heterogeneity of the injected products (biologic agents or calcium phosphate), this approach still lacks strong enough evidence to be fully endorsed. Combined biological treatments, nano-molecular approaches, monoclonal antibodies and ‘personalized’ target therapies are currently under development or under investigation with the aim of expanding our armamentarium against knee OA. Cite this article: EFORT Open Rev 2021;6:501-509. DOI: 10.1302/2058-5241.6.210026

Epigenetic therapy targeting bone marrow mesenchymal stem cells for age-related bone diseases

“…However, the curative effect is unsatisfactory in a certain percentage of patients. Precise and personalized therapy remains the ultimate yet unaccomplished goal [ 129 ].…”

The Emerging Era of Interventional Imaging in Rheumatology: An Overview During the Coronavirus Disease-2019 (COVID-19) Pandemic

“…US provides sizeable therapeutic importance particularly when considered in combination with a sufficient physical therapy program. 49 US-guided intra-articular injection of HA was found effective and safe in the treatment of symptomatic hip OA. 50 …”

The Role of Mechanically-Activated Ion Channels Piezo1, Piezo2, and TRPV4 in Chondrocyte Mechanotransduction and Mechano-Therapeutics for Osteoarthritis

“…In addition to exercise, patients may receive intra-articular injections of hyaluronic acid (HA) or corticosteroids, to increase cartilage lubrication or decrease local inflammation, respectively. HA is a GAGs found in the cartilage and synovial fluid, which provides the joint with lubrication and shock absorbance ( Fusco et al, 2021 ). With OA progression, HA in the synovial fluid usually depolymerizes from high to low molecular weight, resulting in a decline in mechanical and viscoelastic properties of the joint.…”

“…Patients with joint inflammation caused by OA benefit more with corticosteroid injection, compared with HA. However, corticosteroid treatment provides only temporary, short term pain relief ( Ayhan et al, 2014 ; Fusco et al, 2021 ; Primorac et al, 2021 ).…”